In a clinical study of 240 patients with allergic rhinitis who were administered omalizumab for 12 weeks, although symptoms improved in the groups with serum free IgE levels of <20 ng/ml and >40 ng/ml, symptoms improved more markedly in the <20 ng/ml group. The gene discussed is IGHE; the disease is allergic rhinitis.